What Stalevo Treats: Main Uses and Benefits

This medication is commonly used to support patients with certain distressing symptoms, generally assisting with maintaining functional stability. This treatment is relevant for easing symptoms related to increased neurological or muscular activity in adults living with Parkinson's disease (PD).

It is applied in addressing conditions involving episodic or fluctuating manifestations, often referred to as the “wearing-off” phenomenon. This is a pattern where motor symptoms, such as slowness of movement (bradykinesia), muscle stiffness (rigidity), and resting tremor, intensify temporarily, causing them to re-emerge or become more noticeable. The primary therapeutic domain is applied in addressing symptoms in situations where supportive symptom management is appropriate, particularly when patients experience fluctuations. The medication may assist with prolonging the periods of “on” time—the periods during the day when movement is reliable.

---

Quick Fact: Support for Motor Fluctuations
Primary Domain	Stabilization of movement control in Parkinson's disease.
Scenario	Used when symptoms worsen noticeably during fluctuating periods.
Patient Benefit	Supports consistent and prolonged periods of reliable movement (on-time).

Regulatory References

1. European Medicines Agency (EMA) therapeutic overview

Stalevo is indicated for adults with Parkinson's disease who are already being treated with levodopa and a dopa-decarboxylase inhibitor (like carbidopa) but are experiencing end-of-dose motor fluctuations.

Contraindications (Must Not Use)

Use of Stalevo is absolutely prohibited in patients with the following conditions, as stated in regulatory labels:

• Known hypersensitivity (allergy) to levodopa, carbidopa, entacapone, or any excipients.
• Narrow-angle glaucoma or a tumor of the adrenal gland (pheochromocytoma).
• Severe liver impairment.
• History of melanoma or the presence of suspicious, undiagnosed skin lesions.
• Concurrent use of non-selective Monoamine Oxidase (MAO) inhibitors.
• History of Neuroleptic Malignant Syndrome (NMS) or non-traumatic rhabdomyolysis.

Eligibility Restrictions and Caution

Population/Condition	Regulatory Status
Children/Adolescents (under 18)	Safety and efficacy not established; not recommended.
Mild to Moderate Hepatic Impairment	Caution is recommended; dose reduction may be necessary.
Severe Renal Impairment	Administer with caution.
Pregnancy/Lactation	Not recommended or not to be used unless clearly necessary.

Interactions with other medicines and products

Stalevo (carbidopa, levodopa, and entacapone) has officially documented interactions that govern its co-administration with other substances, as detailed in regulatory prescribing information.

---

Prohibited and Restricted Combinations

Classification	Interacting Substance/Group	Required Action
Contraindicated	Non-selective Monoamine Oxidase (MAO) Inhibitors (e.g., phenelzine)	Must be discontinued at least two weeks prior to starting Stalevo.
Caution/Monitoring	Antihypertensive Agents	Dose adjustment of the antihypertensive drug may be necessary due to a risk of symptomatic postural hypotension.
Reduced Efficacy	Dopamine D2 Receptor Antagonists (e.g., metoclopramide)	These agents may reduce the therapeutic effect of levodopa.

---

Pharmacokinetic and Efficacy Considerations

Entacapone, one of Stalevo's components, inhibits the COMT enzyme. Therefore, caution is required with co-administered COMT substrates (e.g., epinephrine, isoproterenol), as their effects may be potentiated. The beneficial effects of levodopa may also be reduced by certain agents, including Phenytoin, Papaverine, and Isoniazid.

Regulatory documents also state that Stalevo's absorption may be compromised by the concurrent intake of Iron Salts (supplements or vitamins) and by consuming a High Protein Diet, as certain amino acids compete with levodopa for transport. Furthermore, in patients taking Warfarin (a CYP2C9 substrate), monitoring of the International Normalized Ratio (INR) is necessary upon initiating Stalevo.

Dual Peripheral Enzyme Protection

The action of Stalevo is defined by the coordinated pharmacodynamics of its three components, engineered to maximize and modulate the delivery of the neurotransmitter precursor Levodopa. Carbidopa and Entacapone are selective enzyme inhibitors acting exclusively in the periphery. Carbidopa blocks the AADC enzyme, while Entacapone blocks the COMT enzyme. By inhibiting both major peripheral breakdown pathways, the combination reduces the formation of inactive metabolites, resulting in a higher and more sustained concentration of intact Levodopa in the blood plasma available for transport across the blood-brain barrier (BBB).

Sustained Central Receptor Activation

Once Levodopa successfully crosses the BBB, it is converted into the active neurotransmitter Dopamine by the remaining AADC enzyme within specific nerve terminals. This newly synthesized Dopamine acts as an agonist on postsynaptic dopamine receptors (e.g., D1 and D2) in the striatum. The sustained peripheral protection ensures this central conversion and subsequent receptor activation are more continuous and stable over time. This targeted modulation of the striatal dopaminergic signaling pathway promotes more continuous signal transmission.

Mechanism Constraint: Pathology Dependence

The long-term effectiveness of the mechanism is constrained by a physiological limitation: the requirement for residual AADC-containing neurons. Levodopa must be converted into Dopamine, a process that relies on the function of surviving nerve terminals in the CNS. As the underlying pathology progresses, the number of functional terminals progressively degenerates, leading to a diminished capacity for conversion, functionally constraining the mechanism.

Stalevo is a fixed-dose medication administered exclusively by the oral route. It is provided as a film-coated tablet and must be swallowed whole, without splitting, crushing, or chewing. The drug is available in several strengths, all containing a fixed 200 mg of entacapone, combined with various doses of levodopa and carbidopa, ranging from 50/12.5/200 mg up to 200/50/200 mg.

The standard adult regimen involves careful titration, where the initial dose is selected to correspond with the patient's existing levodopa treatment. The medicine is taken in multiple daily doses distributed over the patient's waking hours, but only one tablet is to be administered at each scheduled dosing interval. Total usage is limited by the maximum recommended daily dose of entacapone, which generally restricts the overall daily intake to a maximum of eight tablets for most strengths.

Administration Constraints

The tablet may be taken with or without food. Administration should account for diet, as high-protein or high-fat meals may reduce the absorption of the active components. Specific population-based instructions include cautious use and potential dose reduction for patients with hepatic impairment. It is not recommended for use in patients under 18 years of age. Finally, patients are instructed to take iron preparations at least 2 to 3 hours apart from the medication and to not take a double dose to compensate for a missed one.

Research Evidence and Overview of Clinical Studies

Evidence for Use in Managing Motor Fluctuations

The main body of research on this combination therapy, composed of levodopa, carbidopa, and entacapone, was conducted using randomized controlled trials (RCTs). These are studies where participants are randomly assigned to monitor outcomes under controlled conditions. The research examined adult patients with Parkinson's disease who were already taking levodopa/carbidopa but were experiencing conditions characterized by fluctuating or episodic manifestations—specifically, the “wearing-off” phenomenon.

In these trials, researchers primarily monitored outcomes related to daily functioning and activity level. The findings describe patterns observed in the studies where the triple-combination was associated with patterns of measured change in daily "off" time and corresponding change in daily "on" time compared to those receiving standard levodopa/carbidopa alone. Research highlights changes measured during the study period that contribute to the broader evidence landscape.

While the research provides insight into short-term changes, the follow-up durations were limited in the pivotal efficacy trials. This means that although the short-term results are available, there is limited information for long-term outcomes regarding the durability of these measured effects over many years.

---

Long-Term Research and Study Limitations

Research explored the use of this combination therapy in settings beyond the primary indication. One large, long-term randomized controlled trial, known as STRIDE-PD, research examined whether starting the combination therapy early may delay the onset of motor complications. Data from this trial did not align with the study's initial hypothesis regarding the delaying of complications in newly diagnosed patients. Furthermore, the trial was associated with some unexpected outcomes linked to systemic or functional imbalance that were not the focus of the study.

The research results apply only to the populations studied, which were those already experiencing motor fluctuations. The research provides context but findings describe group patterns observed in the trials.

---

Evidence in Patient Subgroups

Studies explored the characteristics of the medication in various subgroups of the general adult population. For instance, research examined how people with differing levels of liver or kidney function may handle the medication. However, data for certain groups remain insufficient. Limited information is available for those under 18 years of age, as this population was not included in the studies. The body of evidence does not provide comprehensive data for all co-occurring conditions.

Key Studies & References Orion: Primary objective of STRIDE-PD study was not achieved (STRIDE-PD trial results release)

Common questions about Stalevo (FAQ)

Q: Is Stalevo the same as taking separate carbidopa, levodopa, and entacapone pills?

A: Regulatory bioequivalence studies describe that taking Stalevo produces a comparable concentration of levodopa, carbidopa, and entacapone in the bloodstream as taking the separate products. This pharmacological approach is designed to provide consistent and stable delivery of the active ingredients.

Q: What happens if a dose of Stalevo is missed?

A: Official product information describes that if a dose is missed, it may be taken as soon as it is remembered, but if it is nearly time for the next scheduled dose, the missed dose should be omitted. A double dose is not recommended to compensate for a missed one.

Q: Do clinical studies show that Stalevo helps with symptoms like stiffness and tremors?

A: Clinical trials were conducted in patients with Parkinson’s disease experiencing motor fluctuations (periods when their medicine was wearing off). The mechanism of action is designed to sustain levodopa levels, and research examined its association with patterns of change in motor symptoms, such as slowness of movement and stiffness.

Q: Why do some people experience hallucinations when taking Stalevo?

A: Hallucinations and other psychotic-like behaviors are listed in regulatory documents as known adverse reactions associated with this type of therapy. This is related to the medicine's mechanism of increasing central dopaminergic tone.

Q: Are there specific times of day that Stalevo is usually taken?

A: According to official instructions, the medicine is taken in multiple daily doses that are typically spread out over a patient's waking hours. Only one tablet is to be administered at each scheduled dosing interval. The total daily usage is carefully managed and distributed.

Q: Is Stalevo ever used for conditions other than Parkinson's disease?

A: Regulatory documents describe Stalevo as being indicated solely for the treatment of patients with idiopathic Parkinson's disease who are experiencing motor fluctuations (wearing-off). This use is for adults already taking levodopa/carbidopa.

Q: Is it known if Stalevo is excreted in breast milk?

A: The official guidance advises against use during lactation, as there is a potential for serious adverse reactions in the infant, according to the product labeling. This caution means the medication should not be used unless the prescribing doctor deems it clearly necessary.

Q: How quickly does Stalevo start working after someone begins taking it?

A: Pharmacokinetic data in the official documents describe that the components of Stalevo are rapidly absorbed. The time to reach the highest concentration in the blood (Tmax) for levodopa and entacapone is approximately one hour after administration.

Q: Does Stalevo have known interactions with common over-the-counter pain relievers?

A: Caution is advised regarding drug interactions. Official information notes that some over-the-counter products may contain ingredients that could interact with Stalevo or increase the risk of side effects like drowsiness.

Q: Do older adults typically experience different side effects from Stalevo compared to younger patients?

A: No overall differences in efficacy or safety were observed between older adult patients (65 years and over) and younger patients in clinical trials. However, the official label notes that greater sensitivity in some older individuals cannot be ruled out.

Q: Can Stalevo cause a metallic taste or dry mouth?

A: Dry mouth has been reported as an adverse reaction experienced by patients taking the medication. Regulatory documents list this as a known side effect.

Q: Is Stalevo known to interact with herbal supplements?

A: Official product information notes that patients should share information with their healthcare provider regarding all concurrent medicines, including herbal products, due to the potential for interactions with Stalevo. Caution regarding potential interaction is advised.

Q: What are the most frequent reasons people stop taking Stalevo?

A: Data from clinical trials describe that withdrawals from treatment due to adverse reactions occurred more frequently in the Stalevo group than in the control group. The most common cause for patients withdrawing from the study was the appearance or worsening of involuntary movements, known as dyskinesia.

Q: Is Stalevo a cure for Parkinson's disease?

A: Official product information describes Stalevo as a prescription medicine used to manage the motor symptoms of Parkinson's disease. It is not considered a cure for the condition.

Q: Can Stalevo be used by people with a history of heart problems?

A: Official warnings describe that patients with a history of serious cardiovascular or heart rhythm problems are advised to use the medication carefully. These conditions are noted as concerns in the product labeling.

Q: Can Stalevo affect vision or cause blurred vision?

A: Blurred vision and difficulty seeing clearly have been reported as side effects. Furthermore, the official labeling indicates that Stalevo is contraindicated (restricted from use) for patients with narrow-angle glaucoma.

Q: What kind of warning labels are on Stalevo packaging?

A: Official documentation includes serious warnings about potential side effects such as falling asleep during daily activities without warning, and the risk of developing Neuroleptic Malignant Syndrome (a severe reaction associated with the nervous system) upon sudden discontinuation. Warnings also cover the potential for depression.

Q: Can Stalevo make existing restlessness worse?

A: The medication is associated with motor side effects, such as dyskinesia (involuntary movements). Regulatory labeling notes that these movement issues or other movement problems can appear or become worse when treatment is initiated.

Q: What should a patient do if they notice a significant change in the effects of Stalevo?

A: Official patient counseling information describes that if patients experience a 'wearing-off' effect, where the medication's effects diminish before the next scheduled dose, this should be discussed with the prescribing healthcare provider. The dose may need to be adjusted by a doctor.

Q: Can Stalevo interact with cold or flu medications?

A: Official labeling advises caution with certain cold or flu medications. This is due to the possibility that some ingredients may interact with Stalevo or increase the risk of side effects like drowsiness.

Q: What scientific data exists about Stalevo and daytime sleepiness?

A: Official documentation notes that patients taking Stalevo have reported daytime drowsiness (somnolence). In rare cases, patients have suddenly fallen asleep without warning while engaged in daily activities.

Q: Can Stalevo affect a person's ability to drive?

A: Due to the risk of dizziness, drowsiness, and suddenly falling asleep without warning, official product information indicates that activities requiring alertness, such as driving or operating machines, should be approached with care.

How to Store and Dispose of Stalevo?

Official regulatory information requires Stalevo to be stored under specific conditions to ensure its stability and effectiveness. The medicine must be kept out of the sight and reach of children at all times.

Storage Requirements

Condition	Requirement
Temperature	Store at room temperature (e.g., below 30 C or 86 F).
Handling	Keep in the original container in a cool, dry place.
Protection	Must be protected from light and moisture.

Disposal Instructions

To prevent environmental contamination and misuse, do not dispose of unused or expired Stalevo by flushing it down a toilet or sink, and do not place it in household trash. Return the medicine to a pharmacist or follow local government instructions for authorized drug take-back or disposal programs. The medication must not be used past the expiry date printed on the package.